Albemarle (ALB) AI Stock Analysis

Albemarle

(BMV:ALB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improved cash generation and lower leverageThe sharp recovery in operating and free cash flow strengthens Albemarle’s ability to fund operations, reduce debt, and preserve strategic flexibility. Lower leverage further improves resilience, although the company’s cash generation remains influenced by the lithium cycle.

Negative Factors

Highly cyclical and weakened profitabilityThe recovery in revenue and profitability remains incomplete after the sharp downturn in 2024–2025. Low current margins and large historical swings show continued sensitivity to lithium pricing and demand, limiting earnings predictability over the next several quarters.

Albemarle (ALB) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 10.74B
Dividend Yield: 1.74%
Average Volume (3M): 191
Price to Earnings (P/E): 189.6
Beta (1Y): 0.41
Revenue Growth: 7.70%
EPS Growth: ―
Country: Mexico
Employees: 7,800
Sector: Basic Materials
Sector Strength: 61
Industry: Chemicals - Specialty

Albemarle Business Overview & Revenue Model

Company Description

Albemarle Corporation stands as a global innovator, producing and distributing a diverse portfolio of engineered specialty chemicals. Its business operations are divided into three principal segments: Lithium, Bromine, and Catalysts. The Lithium divi...

Albemarle Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:-18.88%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call conveyed a strong operational and financial quarter highlighted by robust top‑line growth (net sales +31%), outsized EBITDA expansion (+155%), exceptional cash generation (Q2 cash from operations $710M and $638M FCF) and meaningful cost/productivity gains. Management raised Specialties outlook, advanced DLE pilot results (>90% recoveries) and signaled disciplined capital allocation with attractive brownfield growth options. Offsetting risks include a June fire at Greenbushes (CGP3) that delayed some volume, tight industry inventories and spodumene supply constraints, supply chain impacts from Middle East disruptions (estimated $70–$90M effect), and near‑term margin sensitivity from spodumene price timing. Overall, the positive operational execution, strong cash flow and upgraded outlooks outweigh the near‑term operational and market headwinds.

Positive Updates

Strong Revenue and EBITDA Growth

Second quarter net sales of $1.7 billion, up 31% year‑over‑year; adjusted EBITDA of $858 million, up 155% year‑over‑year; enterprise adjusted EBITDA margin expanded to 49%.

Negative Updates

CGP3 Plant Fire and Volume Impact

Fire at Greenbushes CGP3 on June 9 reduced expected energy storage sales volume; full run rate for CGP3 now assumed in Q1 2027 (slip versus prior internal expectations) and contributed to lower expected Energy Storage volumes for 2026.

Company Guidance

Management said it is maintaining 2026 outlook ranges but expects to land toward the high end of the $20/kg LCE scenario, reflecting Q2 results of $1.7B net sales, $858M adjusted EBITDA (49% enterprise EBITDA margin), $710M cash from operations (>80% operating cash conversion) and $638M free cash flow (net income $480M, EPS $3.52). Key guidance metrics: Energy Storage full‑year sales volumes now expected at 225k–235k t LCE (Q2 = 65k t, avg realized price ≈ $20/kg; Q3 expected sequentially lower), Specialties raised to $1.4–1.6B sales and $275–325M adjusted EBITDA, cost/productivity savings on track to the high end of the $100–150M target (≈$100M run‑rate YTD), reduced capex, and a ~$70–90M estimated unmitigated Middle East supply‑chain impact; CGP3 restarted Aug 1 with full run rate assumed Q1 2027.

Albemarle Risk Analysis

Albemarle disclosed 48 risk factors in its most recent earnings report. Albemarle reported the most risks in the "Production" category.

Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

1 New Risk

1.44foreign currency forward contracts. The sensitivity of the fair value of our foreign currency hedge portfolio represents changes in fair values estimated based on market conditions as of March 31, 2026, without reflecting the effects of underlying anticipated transactions. When those anticipated transactions are realized, actual effects of changing foreign currency exchange rates could have a material impact on our earnings and cash flows in future periods.Q1, 2026

Albemarle Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

MX:ALB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SQM	69Neutral	$15.15B	11.13	23.63%	4.42%	58.56%	189.59%
EMN	65Neutral	$7.61B	11.73	10.63%	5.05%	0.40%	-6.58%
ESI	62Neutral	$8.31B	40.55	7.39%	0.93%	39.62%	-14.83%
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ASH	56Neutral	$3.42B	65.51	2.77%	2.24%	-1.39%	―
CC	43Neutral	$2.04B	-6.76	-170.31%	2.59%	-1.38%	28.10%

* Basic Materials Sector Average

Performance Comparison

MX:ALB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:ALB	Albemarle Corporation	1698.00	-98.25	-5.47%
ASH	Ashland Global Holdings, Inc.	74.68	27.76	59.17%
EMN	Eastman Chemical Company	66.53	11.40	20.67%
SQM	Sociedad Quimica Y Minera	54.65	7.00	14.69%
ESI	Element Solutions	34.27	7.41	27.57%
CC	Chemours Company	13.53	1.12	9.02%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Albemarle AI Stock Analysis